Common blood changes not independent predictor of adverse outcomes for kidney disease patients

Fluctuations in blood composition that often arise from commonly used therapies among kidney disease patients are not an independent predictor of adverse outcomes for European haemodialysis patients, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The results suggest that although haemoglobin variability is common in kidney disease patients, it does not appear to increase their likelihood of dying early.

Research has generated conflicting results on the health impacts that may occur when a person experiences variability in levels of haemoglobin (the component of blood that transports oxygen throughout the body) after taking erythropoiesis stimulating agents (ESAs). These drugs are commonly used to treat anaemia in patients with kidney disease. Unfortunately, ESAs can increase the risk of vascular complications and possibly death when used to boost kidney disease patients' haemoglobin levels to what is considered normal ( 13 g/dL) in the general population. In addition, kidney disease patients often have significant fluctuations in haemoglobin levels when using ESAs.

To see if variability of haemoglobin levels over time may have a negative effect on a patient's health, Kai-Uwe Eckardt, MD (University of Erlangen-Nuremberg, Germany) and his colleagues examined data from 5037 European haemodialysis patients treated over two years. 'We were able to establish that variability in haemoglobin levels experienced by many haemodialysis patients, per se, does not appear to increase the risk of mortality,' said Dr Eckardt. However, the study did find that patients with consistently low levels of haemoglobin (11 g/dL) had 2.34-times the risk of dying during the study period; those whose haemoglobin levels fluctuated between normal and 11 g/dL had 1.74-times the risk of dying during the study period.